Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report

Zuzanna Mielczarek; Beata Trędzbor; Katarzyna Piekarska-Bugiel; Krzysztof Krysta

doi:10.5114/ppn.2023.132474

eISSN: 2720-5371
ISSN: 1230-2813

Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

Otwarty dostęp

3/2023
vol. 32

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Opis przypadku

Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report

Zuzanna Mielczarek

¹

,

Beata Trędzbor

²

,

Katarzyna Piekarska-Bugiel

²

,

Krzysztof Krysta

²

Students’ Scientific Association, Department and Clinic of Rehabilitation Psychiatry, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland
Department and Clinic of Rehabilitation Psychiatry, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland

Adv Psychiatry Neurol 2023; 32 (3): 152–155

DOI: https://doi.org/10.5114/ppn.2023.132474

Data publikacji online: 2023/11/17

Pełna treść artykułu Pobierz cytowanie

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Mielczarek Z, Trędzbor B, Piekarska-Bugiel K, Krysta K. Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2023;32(3):152-155. doi:10.5114/ppn.2023.132474.

APA

Mielczarek, Z., Trędzbor, B., Piekarska-Bugiel, K.,  & Krysta, K. (2023). Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 32(3), 152-155. https://doi.org/10.5114/ppn.2023.132474

Chicago

Mielczarek, Zuzanna, Beata Trędzbor, Katarzyna Piekarska-Bugiel,  and Krzysztof Krysta. 2023. "Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report". Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii 32 (3): 152-155. doi:10.5114/ppn.2023.132474.

Harvard

Mielczarek, Z., Trędzbor, B., Piekarska-Bugiel, K.,  and Krysta, K. (2023). Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 32(3), pp.152-155. https://doi.org/10.5114/ppn.2023.132474

MLA

Mielczarek, Zuzanna et al. "Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report." Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, vol. 32, no. 3, 2023, pp. 152-155. doi:10.5114/ppn.2023.132474.

Vancouver

Mielczarek Z, Trędzbor B, Piekarska-Bugiel K, Krysta K. Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2023;32(3):152-155. doi:10.5114/ppn.2023.132474.

Metryki PlumX:

Purpose
Lurasidon is a relatively new, second-generation antipsychotic drug with an interesting receptor profile. It is considered to be safe and has a low risk of side effects. It is a substance with a multi-receptor mechanism of action: it mainly blocks dopaminergic D₂ and serotonergic 5-HT₂A receptors. According to the Summary of Product Characteristics, the adverse reaction of neutropenia was too rare to enable the estimation of its frequency.

Views
A case of 39-year-old patient is presented in the article, diagnosed with paranoid schizophrenia, who developed neutropenia as a result of treatment with lurasidone. After the discontinuation of lurasidone and recommended supplementation, the blood test results gradually improved and finally reached the normal range.

Comment
This case report shows the need for regular monitoring of blood cell parameters in patients treated with second-generation antipsychotics, as there is a risk of neutrocytopenia or even agranulocitosis.

Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report

Zuzanna Mielczarek 1 , Beata Trędzbor 2 , Katarzyna Piekarska-Bugiel 2 , Krzysztof Krysta 2

Zuzanna Mielczarek

¹

,

Beata Trędzbor

²

,

Katarzyna Piekarska-Bugiel

²

,

Krzysztof Krysta

²